Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Merger or Acquisition (May 2011)
11 slides from Teva Pharmaceutical Industries's merger presentation, May 16, 2011
Slide 1: Teva and TAIYO: Leadership in Japanese Generics
Teva and TAIYO Leadership in Japanese Generics May 16. 2011 1
Slide 2: Forward Looking Statement
Forward Looking Statement The statements, analyses and other information contained herein relating to the proposed acquisition and its effects on financial and operating performance, including estimates for growth, anticipated positions in the Japanese market and shares in such market, the market fo
Slide 3: Introduction to Teva
Introduction to Teva No. 1 generic pharmaceutical company Top 15 global pharmaceutical company Sales of $16B in 2010 Global product portfolio of around 1,480 molecules 40,000 employees
Slide 4: Teva's Global Presence
Teva’s Global Presence Presence in over 60 countries with Sales in 120 countries
Slide 5: Introduction to TAIYO
Introduction to TAIYO #3 in Japanese generic market FY2010 sales: $530M* Over 550 marketed generics products Cutting-edge production facilities *US GAAP 5
Slide 6: Best in Class Pharmaceutical Production Facilities
Best in Class Pharmaceutical Production Facilities Takayama Factory Land Area 171,836㎡ Total Floor Area110,614 ㎡ Kasukabe Factory Land Area 26,442㎡ Total Floor Area 18,731㎡
Slide 7: Teva's Presence in Japan Today
Teva’s Presence in Japan Today Generics API Branded Teva Kowa Joint TAPI Japan Teva KK Venture (Teva 50%) (100% subsidiary of (100% subsidiary of Teva) Teva) 7
Slide 8: Japan: A High Growth Generic Market
Japan: A High Growth Generic Market 2nd largest pharmaceutical market Market size $Bn; 2010 Generics penetration % (volume) 312 75% Government target: 30% penetration by FY2012 96 23% Growth potential Long term potential*: >60% 45 68% penetration 22 63% *Teva estimation Source: IMS Market Prognosis,
Slide 9: Teva + TAIYO: An Excellent Strategic Fit
Teva + TAIYO: An Excellent Strategic Fit + TEVA TAIYO #1 global generics player Strong local footprint Broad portfolio of high quality Wide market reach products Global scale advantages: Best-in-class manufacturing API, R&D and Manufacturing Global presence / Local Dedicated & experienced leadership
Slide 10: Key Transaction Terms
Key Transaction Terms Acquisition of controlling interest (57%) in TAIYO for $460M in cash paid to private shareholders Extended offer to purchase all remaining shares Enterprise value $1.3B Expected closing by the end of Q3/2011 Accretive to earnings on a GAAP basis within 4Q after closing 10
Slide 11: A winning combination
A winning combination 11
Teva Pharmaceutical Industries — Merger or Acquisition (May 2011) on 6ix